Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib

Not Applicable

Not yet recruiting

• Conditions: Rheumatoid Arthritis

• Registration Number: NCT06977035
• Lead Sponsor: Sohag University

Brief Summary

Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). Nerve conduction studies (NCSs) are an essential tool in the evaluation of the peripheral nervous system. The sensory nerve action potential (SNAP) provides information on the sensory nerve axon and its pathway from the distal receptors in the skin to the dorsal root ganglia, while the compound muscle action potential (CMAP) is an assessment of the motor nerve fibers from their origins in the anterior horn cell to their termination along muscle fibers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-04-24
• Status Verified: 2025-05
• Study Start: 2025-05
• Study First Submitted QC: 2025-05-10
• Last Update Submitted: 2025-05-10
• Study First Posted: 2025-05-16
• Last Update Posted: 2025-05-16
• Primary Completion: 2025-11
• Study Completion: 2025-11

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Patients fulfill the 2010 ACR/EULAR classification criteria of RA
2. Age above 18 years old.
3. Patient cooperative and can answer questions

Exclusion Criteria

1. Other rheumatologic or collagen diseases.
2. Age below 18 years and above 65 years.
3. Uncooperative patients.
4. Patients with other causes of peripheral neuropathy as Diabetes mellitus.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
prevalence of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib	6 months	Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib in comparison to those on conventional synthetic DMARDs.